X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Adge has secured a global license to RO269228, a clinical stage oral small molecule originally developed by Roche for osteoporosis. RO269228, also known as elocalcitol, is a vitamin D analog which has demonstrated efficacy and safety in multiple Phase 2 clinical trials.
Lead Product(s): Elocalcitol
Therapeutic Area: Genetic Disease Product Name: RO269228
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adge Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 25, 2022
Details:
Adge Pharmaceuticals has in-licensed RO269228, a clinical stage oral small molecule, for the treatment of Rett syndrome and Osteogenesis imperfecta and potentially other indications with unmet medical needs.
Lead Product(s): Elocalcitol
Therapeutic Area: Musculoskeletal Product Name: RO269228
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adge Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
